
Chinese pharmaceutical manufacturer formally established on 8 November 2012 as a wholly owned subsidiary of China Otsuka Pharmaceutical, with 68.4 million yuan of registered capital and a 51,732 square metre site in Yingchengzi, Ganjingzi district, Dalian, Liaoning holding 27,071 square metres of buildings. Produces large volume parenteral solutions - four products in 22 specifications - at around 150 million bags a year, supplied to provinces and cities across China and reaching almost every second-tier and larger city. Its parent China Otsuka was set up jointly by China Pharmaceutical Investment, part of Sinopharm, and Otsuka Pharmaceutical of Japan as China's first Sino-foreign pharmaceutical joint venture.
Để lại đánh giá